Aya Albittar, MD
@albittara
AspiringOncologist/IM physician/Researcher @fredhutch /MS @MDA_UTHGrad Alumna @UW @UpstateIM_Res @DamascusU @AlbaathU #EndCancer #WomenInSTEM #FMG #HealthEquity
ID: 1163909635574849536
20-08-2019 20:24:26
76 Tweet
124 Takipçi
338 Takip Edilen
#ASH23 Abstract 2126: Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel doi.org/10.1182/blood-… Novel way to look at CAR-T toxicities presented by Dr. Aya Albittar, MD 4/18
ASXL1 mutations were seen in 78% of patients who didn’t respond to donor lymphocyte infusion but 0% of patients who did. Our Dustin McCurry presented this research at #ASH23 and suggested that mutant ASXL1 allows cancer cells to escape immune surveillance by suppressing antigen
Lot of interest generated by Andrew Portuguese’s abstract! #ASH23 2131 Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting ash.confex.com/ash/2023/webpr… ashpublications.org/blood/article/…
Great to see the work of our very talented trainees being presented at #ASH23! Emily Liang and Dr. Wuliji! 2143 Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy ash.confex.com/ash/2023/webpr…
Thank you Jordan Gauthier for your teaching and #mentorship ! #ASH2023
Amazing presentation by Dustin McCurry at #ASH2023 on understanding the mechanism of resistance to donor lymphocyte infusion in ASXL1 mutant patients and its role in regulating HLA-I expression! MD Anderson Cancer Center Pavan Bachireddy Sachet Ashok Shukla
Congratulations Emily Liang and Jordan Gauthier very well deserved!!
Cited Jordan Gauthier in Dr. Andres Gomez slide “thanks to the people supported me in my journey” Thank you Jordan Gauthier for supporting me in my journey :) ASH #ASH2023 Fred Hutch Cancer Center University of Washington #IMG
Swing by Jennifer Huang’s great poster at #ASH23 #3495 Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy doi.org/10.1182/blood-…
Had a great time talking at this ASTCT Spotlight Session today chaired by Dr. Christine Duncan Dana-Farber/Boston Children's. I gave a broad overview of our Fred Hutch Cancer Center long-term follow-up program and recommendations to manage late complications after IEC therapy. Learnt a lot from other
Our postdoctoral fellow Dr. Mohammad Jad Moussa showcased work done under the mentorship of Drs. Matt Campbell MD, MS and Omar Alhalabi, MD on small cell neuroendocrine carcinomas of the urothelial tract at #ASCO24. Mohammad Jad Moussa, MD, MSc ASCO #EndCancer
Thank you so much IMG Oncologists for highlighting our work and for your amazing efforts to support #IMGs 💪ASCO #ASCO24 Petros Grivas Nazli Dizman Toni Choueiri, MD Neeraj Agarwal, MD, FASCO Hedyeh Ebrahimi Sumanta K. Pal, MD, FASCO Wadih Issa, MD Zeynep Irem Ozay, MD Renee Maria Saliby
Infectious complications with BCMA-directed therapies in multiple myeloma; N=147 (CAR-T 92, bispecifics 55). Incidence of severe infections was significantly higher with bispecifics than CAR-T cells #mmsm #bmtsm Blood Cancer Journal Karthik Nath Zainab Shahid MD, FACP, FIDSA 🇺🇸🇵🇰 nature.com/articles/s4140…
Congratulations Dimitra R. Bakaloudi MD, MS, MPA and Petros Grivas !!
Congratulations to all your hard work Mohammad Jad Moussa, MD, MSc !! I am certain that this is only the start for more great work to come! Congratulations Omar Alhalabi, MD & Matt Campbell MD, MS on your dedication and investment in your mentees success and growth! #ASCO24